Keros Therapeutics, Inc. (NASDAQ:KROS) Receives Consensus Rating of “Buy” from Brokerages

Keros Therapeutics, Inc. (NASDAQ:KROS) has been assigned a consensus recommendation of “Buy” from the seven analysts that are presently covering the company, Marketbeat.com reports. Seven investment analysts have rated the stock with a buy rating. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $86.00.

A number of research firms recently issued reports on KROS. HC Wainwright reiterated a “buy” rating and issued a $100.00 target price on shares of Keros Therapeutics in a report on Friday, March 1st. Piper Sandler reiterated an “overweight” rating and issued a $105.00 target price on shares of Keros Therapeutics in a report on Wednesday, March 27th. Truist Financial reiterated a “buy” rating and issued a $100.00 target price on shares of Keros Therapeutics in a report on Wednesday, March 13th. William Blair reiterated an “outperform” rating on shares of Keros Therapeutics in a report on Wednesday, February 21st. Finally, Wedbush restated an “outperform” rating and issued a $86.00 price target on shares of Keros Therapeutics in a research note on Thursday, February 29th.

Institutional Trading of Keros Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Virtus ETF Advisers LLC increased its position in shares of Keros Therapeutics by 7.1% during the fourth quarter. Virtus ETF Advisers LLC now owns 2,743 shares of the company’s stock worth $109,000 after purchasing an additional 182 shares in the last quarter. Wellington Management Group LLP increased its position in shares of Keros Therapeutics by 1.2% during the first quarter. Wellington Management Group LLP now owns 18,984 shares of the company’s stock worth $1,032,000 after purchasing an additional 227 shares in the last quarter. California State Teachers Retirement System increased its position in shares of Keros Therapeutics by 1.9% during the third quarter. California State Teachers Retirement System now owns 19,511 shares of the company’s stock worth $734,000 after purchasing an additional 364 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Keros Therapeutics by 3.2% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 12,898 shares of the company’s stock worth $513,000 after purchasing an additional 404 shares in the last quarter. Finally, Amalgamated Bank increased its position in shares of Keros Therapeutics by 15.6% during the fourth quarter. Amalgamated Bank now owns 3,245 shares of the company’s stock worth $156,000 after purchasing an additional 439 shares in the last quarter. Institutional investors and hedge funds own 71.56% of the company’s stock.

Keros Therapeutics Stock Up 0.6 %

KROS opened at $58.00 on Friday. Keros Therapeutics has a 52 week low of $27.02 and a 52 week high of $73.00. The business has a fifty day simple moving average of $63.41 and a 200-day simple moving average of $46.63. The firm has a market cap of $2.09 billion, a P/E ratio of -11.15 and a beta of 1.27.

Keros Therapeutics (NASDAQ:KROS) last released its earnings results on Friday, March 1st. The company reported ($1.34) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.37) by $0.03. The company had revenue of $0.14 million during the quarter. During the same period in the previous year, the business posted ($1.09) EPS. Sell-side analysts expect that Keros Therapeutics will post -5.11 earnings per share for the current year.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.